keyword
MENU ▼
Read by QxMD icon Read
search

souhami

keyword
https://www.readbyqxmd.com/read/29350599/prognostic-factors-for-progression-in-atypical-meningioma
#1
Shakir I Shakir, Luis Souhami, Kevin Petrecca, Jose João Mansure, Khushdeep Singh, Valerie Panet-Raymond, George Shenouda, Amal A Al-Odaini, Bassam Abdulkarim, Marie-Christine Guiot
OBJECTIVE The optimal adjuvant management for atypical meningiomas remains controversial. The aim of this study was to review long-term outcomes to identify potential prognostic factors for disease progression. METHODS From August 1992 to August 2013, 70 patients with atypical meningioma were treated at the authors' institution. Pathology revision was performed based on WHO 2007 criteria. Patients with multiple tumors, neurofibromatosis Type 2, or inadequate imaging follow-up were not eligible. The authors performed pre- and postoperative serial measurements of tumor volume from MRI...
January 19, 2018: Journal of Neurosurgery
https://www.readbyqxmd.com/read/29204528/serum-testosterone-changes-in-patients-treated-with-radiation-therapy-alone-for-prostate-cancer-on-nrg-oncology-rtog-9408
#2
R Charles Nichols, Chen Hu, Jean-Paul Bahary, Kenneth L Zeitzer, Luis Souhami, Mark H Leibenhaut, Marvin Rotman, Elizabeth M Gore, Alexander G Balogh, David McGowan, Jeff Michalski, Adam Raben, Shari Rudoler, Christopher U Jones, Howard Sandler
Objectives: We reviewed testosterone changes for patients who were treated with radiation therapy (RT) alone on NRG oncology RTOG 9408. Methods and materials: Patients (T1b-T2b, prostate-specific antigen <20 ng/mL) were randomized between RT alone and RT plus 4 months of androgen ablation. Serum testosterone (ST) levels were investigated at enrollment, RT completion, and the first follow-up 3 months after RT. The Wilcoxon signed rank test was used to compare pre- and post-treatment ST levels in patients who were randomized to the RT-alone arm...
October 2017: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/29164521/funding-source-conflict-of-interest-and-positive-conclusions-in-neuro-oncology-clinical-trials
#3
Fabio Y Moraes, Lucas C Mendez, Neil K Taunk, Srinivas Raman, John H Suh, Luis Souhami, Ben Slotman, Eduardo Weltman, Daniel E Spratt, Alejandro Berlin, Gustavo N Marta
We aimed to test any association between authors' conclusions and self-reported COI or funding sources in central nervous system (CNS) studies. A review was performed for CNS malignancy clinical trials published in the last 5 years. Two investigators independently classified study conclusions according to authors' endorsement of the experimental therapy. Statistical models were used to test for associations between positive conclusions and trials characteristics. From February 2010 to February 2015, 1256 articles were retrieved; 319 were considered eligible trials...
November 21, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29143919/iglarlixi-reduces-glycated-hemoglobin-to-a-greater-extent-than-basal-insulin-regardless-of-levels-at-screening-post-hoc-analysis-of-lixilan-l
#4
Elisabeth Niemoeller, Elisabeth Souhami, Yujun Wu, Klaus H Jensen
INTRODUCTION: The treatment of patients with type 2 diabetes uncontrolled on basal insulin and oral glucose-lowering drugs was investigated previously in the LixiLan-L trial. In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks. In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA1c) levels from screening, both for the overall category and for screening HbA1c subcategories...
November 16, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29102648/investigating-the-effect-of-reirradiation-or-systemic-therapy-in-patients-with-glioblastoma-after-tumor-progression-a-secondary-analysis-of-nrg-oncology-radiation-therapy-oncology-group-trial-0525
#5
Wenyin Shi, Molly Scannell Bryan, Mark R Gilbert, Minesh P Mehta, Deborah T Blumenthal, Paul D Brown, Egils Valeinis, Kirsten Hopkins, Luis Souhami, David W Andrews, Tzahala Tzuk-Shina, Steve P Howard, Emad F Youssef, Nathalie Lessard, James J Dignam, Maria Werner-Wasik
PURPOSE: To determine the impact on overall survival with different salvage therapies, including no treatment, reirradiation, systemic therapy, or radiation and systemic therapy, in participants of a phase 3 clinical trial evaluating dose-dense versus standard-dose temozolomide for patients with newly diagnosed glioblastoma. METHODS AND MATERIALS: This analysis of patients from Trial RTOG 0525 investigated the effect of reirradiation or systemic treatment after tumor progression...
September 4, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28870791/performance-of-knowledge-based-radiation-therapy-planning-for-the-glioblastoma-disease-site
#6
Avishek Chatterjee, Monica Serban, Bassam Abdulkarim, Valerie Panet-Raymond, Luis Souhami, George Shenouda, Siham Sabri, Bertrand Jean-Claude, Jan Seuntjens
PURPOSE: The presence of multiple serial organs at risk (OARs) in close proximity to the tumor makes treatment planning for glioblastoma (GBM) complex and time consuming. The present study aimed to create a knowledge-based (KB) radiation therapy model for GBM patients using RapidPlan. METHODS AND MATERIALS: An initial model was trained using 82 glioblastoma patients treated with 60 Gy in 30 fractions. Plans were created using either volumetric modulated arc therapy (VMAT) or intensity modulated radiation therapy (IMRT)...
November 15, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28516155/phase-i-clinical-trial-of-everolimus-combined-with-trimodality-therapy-in-patients-with-muscle-invasive-bladder-cancer
#7
Bassel G Bachir, Luis Souhami, Jose João Mansure, Fabio Cury, Marie Vanhuyse, Fadi Brimo, Armen G Aprikian, Simon Tanguay, Jeremy Sturgeon, Wassim Kassouf
Background: Local control following trimodality therapy (TMT) for muscle-invasive bladder cancer (MIBC) requires further optimization. Objective: Evaluating the biologic endpoint, feasibility, and toxicity of integrating everolimus to TMT in patients with MIBC. Methods: This was a phase I trial in patients with MIBC who were not surgical candidates or who refused cystectomy. Following maximal transurethral tumor resection, patients were treated by radiotherapy (50 Gy/20 fractions), gemcitabine (100 mg/m2/weekly) and escalating doses of everolimus (2...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28432746/impact-of-baseline-glycated-haemoglobin-diabetes-duration-and-body-mass-index-on-clinical-outcomes-in-the-lixilan-o-trial-testing-a-titratable-fixed-ratio-combination-of-insulin-glargine-lixisenatide-iglarlixi-vs-insulin-glargine-and-lixisenatide-monocomponents
#8
Melanie J Davies, Lawrence A Leiter, Bruno Guerci, George Grunberger, F Javier Ampudia-Blasco, Christine Yu, William Stager, Elisabeth Niemoeller, Elisabeth Souhami, Julio Rosenstock
To determine whether baseline characteristics had an impact on clinical outcomes in the LixiLan-O trial (N = 1170), we compared the efficacy and safety of iGlarLixi, a titratable fixed-ratio combination of insulin glargine 100 U (iGlar) and lixisenatide (Lixi) with iGlar or Lixi alone in patients with uncontrolled type 2 diabetes mellitus (T2DM) on oral therapy. Subgroups according to baseline glycated haemoglobin (HbA1c; <8% or ≥8% [<64 or ≥64 mmol/mol]), T2DM disease duration (<7 or ≥7 years) and body mass index (BMI; <30 or ≥30 kg/m(2) ) were investigated...
April 22, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28428368/erratum-efficacy-and-safety-of-lixilan-a-titratable-fixed-ratio-combination-of-insulin-glargine-plus-lixisenatide-in-type-2-diabetes-inadequately-controlled-on-basal-insulin-and-metformin-the-lixilan-l-randomized-trial-diabetes-care-2016-39-1972-1980
#9
Vanita R Aroda, Julio Rosenstock, Carol Wysham, Jeffrey Unger, Diego Bellido, Guillermo González-Gálvez, Akane Takami, Hailing Guo, Elisabeth Niemoeller, Elisabeth Souhami, Richard M Bergenstal
No abstract text is available yet for this article.
June 2017: Diabetes Care
https://www.readbyqxmd.com/read/28420696/erratum-benefits-of-lixilan-a-titratable-fixed-ratio-combination-of-insulin-glargine-plus-lixisenatide-versus-insulin-glargine-and-lixisenatide-monocomponents-in-type-2-diabetes-inadequately-controlled-on-oral-agents-the-lixilan-o-randomized-trial-diabetes
#10
Julio Rosenstock, Ronnie Aronson, George Grunberger, Markolf Hanefeld, PierMarco Piatti, Pierre Serusclat, Xi Cheng, Tianyue Zhou, Elisabeth Niemoeller, Elisabeth Souhami, Melanie Davies
No abstract text is available yet for this article.
June 2017: Diabetes Care
https://www.readbyqxmd.com/read/28388591/genetic-landscape-of-extreme-responders-with-anaplastic-oligodendroglioma
#11
Matthias Holdhoff, Gregory J Cairncross, Thomas M Kollmeyer, Ming Zhang, Peixin Zhang, Minesh P Mehta, Maria Werner-Wasik, Luis Souhami, Jean-Paul Bahary, Young Kwok, Alan C Hartford, Arnab Chakravarti, Srinivasan Yegnasubramanian, Bert Vogelstein, Nickolas Papadopoulos, Kenneth Kinzler, Robert B Jenkins, Chetan Bettegowda
BACKGROUND: The NRG Oncology RTOG 9402 trial showed significant survival benefit in patients with 1p/19q co-deleted anaplastic oligodendrogliomas (AO) who received both radiation (RT) and chemotherapy (PCV regimen) versus RT alone. Substantial separation of the survival curves was only seen after 7.3 years. We aimed to determine whether there are specific genetic alterations that distinguish co-deleted AO patients who benefit from the addition of PCV from those who do not. METHODS: We performed whole exome sequencing on matched tumor and normal DNA from all available short-term (STS) and long-term survivors (LTS) who received RT+PCV...
May 30, 2017: Oncotarget
https://www.readbyqxmd.com/read/28386990/consistent-findings-in-glycaemic-control-body-weight-and-hypoglycaemia-with-iglarlixi-insulin-glargine-lixisenatide-titratable-fixed-ratio-combination-vs-insulin-glargine-across-baseline-hba1c-bmi-and-diabetes-duration-categories-in-the-lixilan-l-trial
#12
Carol Wysham, Riccardo C Bonadonna, Vanita R Aroda, Manuel Puig Domingo, Christoph Kapitza, William Stager, Christine Yu, Elisabeth Niemoeller, Elisabeth Souhami, Richard M Bergenstal
AIMS: To assess the impact of baseline characteristics on clinical outcomes in the LixiLan-L trial, a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks in a population of patients with type 2 diabetes mellitus (T2DM) inadequately controlled on a previous regimen of basal insulin alone or in combination with 1 or 2 oral glucose-lowering drugs...
October 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28374095/benefit-of-re-operation-and-salvage-therapies-for-recurrent-glioblastoma-multiforme-results-from-a-single-institution
#13
M Azoulay, F Santos, G Shenouda, K Petrecca, A Oweida, M C Guiot, S Owen, V Panet-Raymond, L Souhami, Bassam S Abdulkarim
The optimal management of recurrent glioblastoma (GBM) has yet to be determined. We aim to assess the benefits of re-operation and salvage therapies (chemotherapy and/or re-irradiation) for recurrent GBM and to identify prognostic factors associated with better survival. All patients who underwent surgery for GBM between January 2005 and December 2012 followed by adjuvant radiotherapy, and who developed GBM recurrence on imaging were included in this retrospective study. Univariate and multivariate analysis was performed using Cox models in order to identify factors associated with overall survival (OS)...
May 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28333021/a-phase-1-2-trial-of-a-combination-of-paclitaxel-and-trastuzumab-with-daily-irradiation-or-paclitaxel-alone-with-daily-irradiation-after-transurethral-surgery-for-noncystectomy-candidates-with-muscle-invasive-bladder-cancer-trial-nrg-oncology-rtog-0524
#14
M Dror Michaelson, Chen Hu, Huong T Pham, Douglas M Dahl, Chin Lee-Wu, Gregory P Swanson, Jacqueline Vuky, R Jeffrey Lee, Luis Souhami, Brian Chang, Asha George, Howard Sandler, William Shipley
PURPOSE: Bladder preservation therapy is an effective treatment for muscle-invasive urothelial carcinoma (UC). In this study we treated noncystectomy candidates with daily radiation and weekly paclitaxel for 7 weeks. Patients whose tumors showed her2/neu overexpression were additionally treated with weekly trastuzumab. METHODS AND MATERIALS: Sixty-eight evaluable patients were treated with radiation therapy and either paclitaxel + trastuzumab (group 1) or paclitaxel alone (group 2)...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28325618/thoracic-irradiation-in-3weeks-for-limited-stage-small-cell-lung-cancer-is-twice-a-day-fractionation-really-needed
#15
REVIEW
G A Turgeon, L Souhami, N Kopek, V Hirsh, L Ofiara, S L Faria
PURPOSE: Many Canadian institutions treat limited-disease small cell lung cancer with 40Gy in 15 fractions delivered once-a-day in 3weeks concomitantly with chemotherapy. This regimen is convenient and seems to be effective. Here, we report and compare with a literature review the outcomes of patients with limited-stage small cell lung cancer treated in our institution with this hypofractionated regimen. PATIENTS AND METHODS: From January 2004 to December 2012, patients with limited-stage small cell lung cancer treated curatively with platinum-based chemotherapy and concurrent thoracic radiotherapy at a dose of 40Gy in 16 fractions once-a-day were eligible for this review...
April 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28222995/acute-and-late-toxicity-in-high-risk-prostate-cancer-patients-treated-with-androgen-suppression-and-hypofractionated-pelvic-radiation-therapy
#16
Sergio Faria, Russel Ruo, Fabio Cury, Marie Duclos, Luis Souhami
PURPOSE: To report acute and late toxicity rates in patients with high-risk prostate cancer treated with androgen deprivation therapy (ADT) and moderate hypofractionated radiation therapy (HypoRT) to the prostate and nodal areas. METHODS AND MATERIALS: Patients with localized, high-risk prostate cancer were treated with a HypoRT regimen of 60 Gy in 20 fractions (4 weeks) to the prostate volume while the nodal areas received 44 Gy in the same 20 fractions delivered with intensity modulated RT with a simultaneous integrated boost technique...
January 20, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28146658/radiation-with-or-without-antiandrogen-therapy-in-recurrent-prostate-cancer
#17
RANDOMIZED CONTROLLED TRIAL
William U Shipley, Wendy Seiferheld, Himanshu R Lukka, Pierre P Major, Niall M Heney, David J Grignon, Oliver Sartor, Maltibehn P Patel, Jean-Paul Bahary, Anthony L Zietman, Thomas M Pisansky, Kenneth L Zeitzer, Colleen A F Lawton, Felix Y Feng, Richard D Lovett, Alexander G Balogh, Luis Souhami, Seth A Rosenthal, Kevin J Kerlin, James J Dignam, Stephanie L Pugh, Howard M Sandler
BACKGROUND: Salvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level. Whether antiandrogen therapy with radiation therapy will further improve cancer control and prolong overall survival is unknown. METHODS: In a double-blind, placebo-controlled trial conducted from 1998 through 2003, we assigned 760 eligible patients who had undergone prostatectomy with a lymphadenectomy and had disease, as assessed on pathological testing, with a tumor stage of T2 (confined to the prostate but with a positive surgical margin) or T3 (with histologic extension beyond the prostatic capsule), no nodal involvement, and a detectable PSA level of 0...
February 2, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28097324/molecular-based-recursive-partitioning-analysis-model-for-glioblastoma-in-the-temozolomide-era-a-correlative-analysis-based-on-nrg-oncology-rtog-0525
#18
RANDOMIZED CONTROLLED TRIAL
Erica Hlavin Bell, Stephanie L Pugh, Joseph P McElroy, Mark R Gilbert, Minesh Mehta, Alexander C Klimowicz, Anthony Magliocco, Markus Bredel, Pierre Robe, Anca-L Grosu, Roger Stupp, Walter Curran, Aline P Becker, Andrea L Salavaggione, Jill S Barnholtz-Sloan, Kenneth Aldape, Deborah T Blumenthal, Paul D Brown, Jon Glass, Luis Souhami, R Jeffrey Lee, David Brachman, John Flickinger, Minhee Won, Arnab Chakravarti
Importance: There is a need for a more refined, molecularly based classification model for glioblastoma (GBM) in the temozolomide era. Objective: To refine the existing clinically based recursive partitioning analysis (RPA) model by incorporating molecular variables. Design, Setting, and Participants: NRG Oncology RTOG 0525 specimens (n = 452) were analyzed for protein biomarkers representing key pathways in GBM by a quantitative molecular microscopy-based approach with semiquantitative immunohistochemical validation...
June 1, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28032465/diurnal-glucose-exposure-profiles-of-patients-treated-with-lixisenatide-before-breakfast-or-the-main-meal-of-the-day-an-analysis-using-continuous-glucose-monitoring
#19
Richard M Bergenstal, Ellie Strock, Roger Mazze, Margaret A Powers, Arlene M Monk, Sara Richter, Elisabeth Souhami, Bo Ahrén
BACKGROUND: In the parent study of this analysis, patients with type 2 diabetes received lixisenatide before breakfast or the main meal of the day. This substudy was designed to examine the effect of lixisenatide administered before breakfast or the main meal of the day on continuously assessed 24-hour patient glucose profiles. METHODS: A subset of patients from the parent study underwent 2 14-day periods of continuous glucose monitoring (CGM) at the start and end of the 24-week study...
December 29, 2016: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/28011051/a-phase-2-trial-of-neoadjuvant-temozolomide-followed-by-hypofractionated-accelerated-radiation-therapy-with-concurrent-and-adjuvant-temozolomide-for-patients-with-glioblastoma
#20
George Shenouda, Luis Souhami, Kevin Petrecca, Scott Owen, Valerie Panet-Raymond, Marie-Christine Guiot, Andrea Gomez Corredor, Bassam Abdulkarim
PURPOSE: We performed a phase 2 trial of neoadjuvant temozolomide (TMZ), followed by hypofractionated accelerated radiation therapy (HART) with concurrent TMZ, and adjuvant TMZ in patients with newly diagnosed glioblastoma to determine whether neoadjuvant TMZ would safely improve outcomes in this group of patients prior to subsequent cytotoxic therapy. METHODS AND MATERIALS: Adult patients with newly diagnosed glioblastoma and a Karnofsky Performance Status >60 were eligible...
March 1, 2017: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
14147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"